drugset / Trial / NCT05316129
Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
Phase 1
Recruiting
10 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Anixa Biosciences, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this first in human study is to evaluate the safety of treatment with autologous T cells genetically modified to express a CER (chimeric endocrine receptor) targeting the FSHR (follicle-stimulating hormone receptor) (FSHCER T cells), with or without conditioning chemotherapy, in participants with recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer.
Timeline
- Start
- 2022-04-28
- Primary completion
- 2026-07
- Completion
- 2029-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Follicle Stimulating Hormone Receptor T Cells | Cell therapy | 100000 cells | Intravenous |
| Subject | Follicle Stimulating Hormone Receptor T Cells | Cell therapy | 300000 cells | Intravenous |
| Subject | Follicle Stimulating Hormone Receptor T Cells | Cell therapy | 1e+06 cells | Intravenous |
| Subject | Follicle Stimulating Hormone Receptor T Cells | Cell therapy | 3e+06 cells | Intravenous |
| Subject | Follicle Stimulating Hormone Receptor T Cells | Cell therapy | 1e+07 cells | Intravenous |